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Since the start of the severe acute respiratory syn-drome coronavirus 2 (SARS-CoV-2) pandemic, 
millions of infections have been confi rmed through 
real-time reverse transcription PCR (RT-PCR) testing 
(1), and millions probably have gone undocument-
ed (2). Two key questions remain unanswered. Has 
any community reached herd immunity to render 
infection transmission chains unsustainable? What 
proportion of the population needs to be infected to 
reach herd immunity?
Qatar, a peninsula in the Arabian Gulf region that 
has a diverse population of 2.8 million (3), has expe-
rienced a large-scale SARS-CoV-2 epidemic (4,5). By 
January 14, 2021, the rate of real-time RT-PCR–con-
fi rmed infections exceeded 65 cases/1,000 persons 
(6). The epidemic, which is currently in an advanced 
stage (4), seems to have followed a classic susceptible-
infected-recovered pattern, with an epidemic peak 
around May 20, followed by a steady decrease for the 
next 8 months (4).
The subpopulation most affected by this epi-
demic was expatriate craft and manual workers 
(CMWs) among whom community transmission was 
fi rst identifi ed (4). These workers constitute ≈60% of 
the population in Qatar and are typically single men 
20–49 years of age (7). CMWs at a given workplace 
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using an electrochemiluminescence immunoassay. Sero-
positivity	 ranged	 from	54.9%	 (95%	CI	 50.2%–59.4%)	 to	
83.8%	 (95%	CI	 79.1%–87.7%)	across	 communities	 and	
showed	a	pooled	mean	of	66.1%	(95%	CI	61.5%–70.6%).	









or company not only work together during the day 
but also live together as a community in large dor-
mitories or housing complexes in which they share 
rooms, bathrooms, and cafeteria-style meals (4,8). 
These communities stay mostly in contact with their 
own community members and infrequently min-
gle with other communities, creating a geographic 
bubble that proved essential for the pattern of infec-
tion transmission (4). With reduced options for ef-
fective social and physical distancing, SARS-CoV-2 
transmission in these CMW communities resembled 
that of influenza outbreaks in schools (4,9,10), and 
especially boarding schools (10). This finding is 
observed despite implementation of nonpharma-
ceutical control measures, such as a mask mandate 
after the World Health Organization (WHO) recom-
mendation (11), promotion and facilitation of social 
and physical distancing, disinfection of surfaces, 
and awareness messaging in different languages. 
A similar transmission pattern has been document-
ed among migrant workers in Singapore (12,13) 
and Spain (14).
Factors observed included the large number of 
diagnosed infections in CMWs (4), the large propor-
tion of infections that were asymptomatic (4,15,16), 
the high real-time RT-PCR positivity rates in the ran-
dom testing campaigns conducted around the epi-
demic peak in different CMW communities (4), the 
observed susceptible-infected-recovered epidemic 
curve with steady decreases in incidence for 8 months 
despite the gradual easing of the social and physical 
distancing restrictions (4,17), and evidence indicating 
an efficacy >90% for natural infection against reinfec-
tion that lasts for >7 months (18; L.J. Abu-Raddad et 
al., unpub. data). All of these factors raised questions 
of whether herd immunity might have been reached 
in at least some of these communities.
On the basis of these considerations, we hypoth-
esized that at least some of the CMW communities 
have already reached the herd immunity threshold. 
To investigate this hypothesis, our specific objective 
was to assess the proportion of the population that 
has been infected by assessing the level of detectable 
antibodies. More than 90% of real-time RT-PCR–con-
firmed cases in Qatar show development of detectable 
antibodies (4); therefore, we operationally defined 
herd immunity as the proportion of the population 
that needs to have detectable antibodies before infec-
tion transmission/circulation becomes unsustainable 
in this population, with limited if any new infections 
occurring. The study was conducted to inform the na-




We conducted testing for detectable SARS-CoV-2–
specific antibodies in blood specimens in 10 CMW 
communities during June 21–September 9, 2020. This 
testing was part of an a priori–designed study com-
bined with a testing and surveillance program led by 
the Ministry of Public Health and Hamad Medical 
Corporation (HMC), the main public healthcare pro-
vider in Qatar and the nationally designated provider 
for all COVID-19 healthcare needs. The goal of this 
program was to assess the level of infection exposure 
in different subpopulations and economic sectors.
The study design was opportunistic using the 
Ministry of Public Health–HMC program and the 
need for rapid data collection to inform the nation-
al response. We specifically selected the 10 CMW 
communities for feasibility or given earlier random 
real-time RT-PCR testing campaigns or contact trac-
ing that suggested substantial infection levels. For 
instance, CMW community 1 was part of a random 
real-time RT-PCR testing campaign that identified, by 
using nasopharyngeal swab specimens, a high posi-
tivity rate of 59% during late April 2020.
The population size of each of these communities 
ranged from a few hundred to a few thousand who 
live in shared accommodations provided by the em-
ployers. The companies that employ these workers 
belonged to the service or industrial sectors, but the 
bulk of the employees, even in the industrial compa-
nies, worked on providing services, such as catering, 
cleaning, and other janitorial services, warehousing, 
security, and port work.
Ten employers were contacted and were willing 
to participate and advertise the availability and loca-
tion of testing sites to their employees. Participation 
was voluntary. Employees interested in being tested 
and in knowing their status were provided with trans-
portation to HMC testing sites. Informed consent was 
able to be obtained in 9 languages (Arabic, Bengali, 
English, Hindi, Urdu, Nepali, Sinhala, Tagalog, and 
Tamil) to cater to the main language groups spoken 
in the CMW communities of Qatar.
We used self-administered questionnaires in 
these same languages only for CMW community 1; 
questionnaires were given by trained public health 
workers to collect data on sociodemographics and 
history of exposure and symptoms. We developed the 
questionnaire on the basis of suggestions from WHO 
(19). A blood specimen was obtained from all study 
participants, and in 6 communities, nasopharyngeal 
swab specimens were simultaneously collected for 
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real-time RT-PCR testing by licensed nurses. We ap-
plied national guidelines and standard of care to all 
identified real-time RT-PCR–positive case-patients, 
including requirement of isolation and other mea-
sures to prevent infection transmission. No action 
was mandated by the national guidelines to those 
persons found to be antibody positive but real-time 
RT-PCR negative, and thus no action was taken apart 
from notifying persons of their serostatus.
We subsequently linked results of the serologic 
testing to the HMC centralized and standardized da-
tabase comprising all SARS-CoV-2 real-time RT-PCR 
testing conducted in Qatar since the start of the epi-
demic (4). The database also includes data on hospi-
talization and on the WHO severity classification (20) 
for each real-time RT-PCR–confirmed infection. Data 
were also linked to datasets of 2 recently completed 
national reinfection studies (18; L.J. Abu-Raddad et 
al., unpub. data) to identify reinfections. The study 
was approved by HMC and Weill Cornell Medicine–
Qatar Institutional Review Boards.
Laboratory Methods
We performed testing for SARS-CoV-2–specific anti-
bodies in serologic samples by using an electroche-
miluminescence immunoassay (Roche Elecsys Anti-
SARS-CoV-2, https://www.roche.com) (sensitivity 
99.5%, specificity 99.8%) (21,22). We interpreted re-
sults according to the manufacturer’s instructions: 
reactive for a cutoff index ≥1.0 and nonreactive for a 
cutoff index <1.0 (22).
We performed real-time RT-PCR testing of ali-
quots of universal transport medium (Huachenyang 
Technology, https://szhcy.en.alibaba.com) used for 
collection of nasopharyngeal swab specimens. We ex-
tracted aliquots by using the QIAsymphony Platform 
(QIAGEN, https://www.qiagen.com); tested them 
by using real-time PCR (TaqPath COVID-19 Combo 
Kit; Thermo Fisher Scientific, https://www.thermo-
fisher.com (sensitivity 100%, specificity 100%) (23) in 
an ABI 7500 FAST System (ThermoFisher); extracted 
them by using a custom protocol (M.K. Kalikiri et al., 
Sidra Medicine, pers. comm., 2021 Feb 1)  on a Ham-
ilton Microlab STAR (https://www.hamiltoncompa-
ny.com); tested them by using the AccuPower SARS-
CoV-2 Real-Time RT-PCR Kit (Bioneer, https://www.
bioneer.com) (sensitivity 100%, specificity 100%) 
(24) on an ABI 7500 FAST System or loaded them di-
rectly into a Roche Cobas 6800 system; and assayed 
them by using the Cobas SARS-CoV-2 Test (sensitiv-
ity 95%, specificity 100%) (25). All laboratory testing 
was conducted at HMC Central Laboratory following 
standardized protocols.
Statistical Analysis
We used frequency distributions to describe charac-
teristics of CMWs and to estimate different SARS-
CoV-2 epidemiologic measures. We estimated the 
pooled mean for SARS-CoV-2 seropositivity across 
CMW communities by using meta-analysis. We ap-
plied a DerSimonian-Laird random-effects model (26) 
to pool seroprevalence measures that were weighted 
by using the inverse-variance method (27,28).
We used χ2 tests and univariable logistic regressions 
to determine the association of each prespecified covari-
ate (i.e., sex, age, nationality, and CMW community) 
with seropositivity. For CMW community 1, we also 
investigated associations of educational attainment, 
contact with an infected person, presence of symptoms 
in the previous 2 weeks, and whether symptoms re-
quired medical attention with seropositivity. Missing 
values were included as separate subcategories in the 
analyses. We generated summary statistics, as well as 
odds ratios (ORs), 95% CIs, and p values (Tables 1, 2; 
Appendix Tables 1, 2, https://wwwnc.cdc.gov/EID/
article/27/5/20-4365-App1.pdf).
We performed multivariable logistic regressions 
to estimate the magnitude of the association of a spe-
cific covariate adjusting for other covariates in the 
model. Covariates with p values <0.2 in univariable 
regression analysis were included simultaneously in 
the multivariable logistic regression model. Covari-
ates with p values <0.05 in the multivariable model 
were considered as showing evidence for an associa-
tion with the outcome, and associated adjusted ORs 
(aORs), 95% CIs, and p values were generated and re-
ported (Tables 1, 2; Appendix Tables 1, 2). No interac-
tions were investigated. Statistical models’ goodness 
of fit were reported. The distribution of real-time RT-
PCR cycle threshold (Ct) values for persons who were 
real-time RT-PCR positive was further generated, and 
summary statistics were reported. Statistical analyses 
were performed by using STATA/SE version 16.1 
(https://www.stata.com) (29).
We also conducted mathematical modeling 
simulations to highlight the effect of heterogeneity 
in the risk for exposure to the infection on the level 
of herd immunity. These simulations were gener-
ated by using a classic age-structured, susceptible-
exposed-infectious-recovered mathematical model 
published elsewhere (17). Simulations were imple-
mented by using MATLAB R2019a (https://www.
mathworks.com) (30).
Results
A total of 4,970 CMWs from the 10 CMW communi-
ties participated in this study (Table 1). Participants 
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were mostly men (95.0%); <40 years of age (71.5%); 
and of Nepalese (43.0%), Indian (33.1%), or Bangla-
deshi (11.6%) origin. Regression analyses identified 
each of sex, nationality, and CMW community to be 
independently associated with seropositivity.
Women had 87% lower odds of being seroposi-
tive than men (aOR 0.13, 95% CI 0.09–0.19) (Table 1). 
Compared with all other nationalities (Table 1), aOR 
was 6.78 (95% CI 4.31–10.66) for Bangladeshis, 4.93 
(95% CI 3.27–7.42) for Nepalese, 3.60 (95% CI 2.40–
5.41) for Indians, 3.43 (95% CI 1.99–5.90) for Kenyans, 
2.81 (95% CI 1.66–4.76) for Sri Lankans, and 2.23 (95% 
CI 1.32–3.75) for Filipinos. Some differences in sero-
positivity by CMW community were noted (Table 1). 
No major differences in seropositivity by age group 
were found (Table 1).
We provide characteristics and associations with 
seropositivity (detectable antibodies in serologic sam-
ples) for only CMW community 1, in which a specific 
self-administered questionnaire was administered 
and collected specific sociodemographic data and his-
tory of exposure and symptoms (Table 2). Nearly 40% 
of participants had intermediate or low educational 
attainment, and 31% had higher schooling levels or 
vocational training. University education was asso-
ciated with a 75% (OR 0.25, 95% CI 0.09–0.67) lower 
odds of seropositivity compared with intermediate or 
lower educational attainment. No significant associa-
tions with seropositivity were found for contact with 
an infected person, presence of symptoms, or symp-
toms requiring medical attention. We provide charac-
teristics and associations with SARS-CoV-2 seroposi-
tivity for CMW communities 2–10 (Appendix Table 
1). For each of these communities, associations were 
found for sex and nationality, but no major associa-
tions were found for age group.
We provide key SARS-CoV-2 epidemiologic mea-
sures in the different CMW communities (Figure 1). 
Of 4,970 SARS-CoV-2 antibody test results for these 















No. %§	(95%	CI) p	value OR	(95%	CI) p	value¶ OR	(95%	CI) p	value# 
Sex           
 M 4,721	(95.0) 3,153 66.8	(65.4–68.1) <0.001  Referent   Referent  
 F 249	(5.0) 46 18.5	(13.9–23.9)   0.11	(0.08–0.16) <0.001  0.13	(0.09–0.19) <0.001 
Age, y           
 <29 1,579	(31.8) 1,031 65.3	(62.9–67.6) <0.001  Referent   Referent  
 30–39 1,973	(39.7) 1,226 62.1	(60.0–64.3)   0.87	(0.76–1.00) 0.052  0.90	(0.78–1.05) 0.178 
 40–49 1,040	(20.9) 680 65.4	(62.4–68.3)   1.00	(0.85–1.18) 0.962  1.12	(0.93–1.35) 0.216 
 >50 339	(6.8) 225 66.4	(61.1–71.4)   1.05	(0.82–1.34) 0.705  1.21	(0.92–1.59) 0.170 
 Missing 39	(0.8) 37 94.9	(82.7–99.4)   9.83	(2.36–40.95) 0.002  9.57	(2.22–41.32) 0.002 
Nationality           
 Other** 125	(2.5) 40 32.0	(23.9–40.9) <0.001  Referent   Referent  
 Filipino 186	(3.7) 68 36.6	(29.6–43.9)   1.22	(0.76–1.98) 0.408  2.23	(1.32–3.75) 0.003 
 Sri Lankan 147	(3.0) 77 52.4	(44.0–60.7)   2.34	(1.42–3.84) 0.001  2.81	(1.66–4.76) <0.001 
 Kenyan 152	(3.1) 77 50.7	(42.4–58.9)   2.18	(1.33–3.57) 0.002  3.43	(1.99–5.90) <0.001 
 Indian 1,647	(33.1) 1,035 62.8	(60.5–65.2)   3.59	(2.44–5.30) <0.001  3.60	(2.40–5.41) <0.001 
 Nepalese 2,136	(43.0) 1,468 68.7	(66.7–70.7)   4.67	(3.17–6.88) <0.001  4.93	(3.27–7.42) <0.001 
 Bangladeshi 577	(11.6) 434 75.2	(71.5–78.7)   6.45	(4.23–9.82) <0.001  6.78	(4.31–10.66) <0.001 
CMW	community           
 5 443	(8.9) 243 54.9	(50.1–59.6) <0.001  Referent   Referent  
 4 534	(10.7) 330 61.8	(57.5–65.9)   1.33	(1.03–1.72) 0.028  1.12	(0.83–1.52) 0.449 
 10 957	(19.3) 620 64.8	(61.7–67.8)   1.51	(1.20–1.90) <0.001  1.30	(1.02–1.65) 0.034 
 7 188	(3.8) 122 64.9	(57.6–71.7)   1.52	(1.07–2.17) 0.020  1.31	(0.91–1.89) 0.154 
 6 1,505	(30.3) 946 62.9	(60.4–65.3)   1.39	(1.12–1.73) 0.002  1.32	(1.06–1.66) 0.015 
 2 456	(9.2) 282 61.8	(57.2–66.3)   1.33	(1.02–1.74) 0.034  1.46	(1.08–1.96) 0.013 
 9 202	(4.1) 126 62.4	(55.3–69.1)   1.36	(0.97–1.92) 0.074  1.71	(1.18–2.48) 0.005 
 8 139	(2.8) 93 66.9	(58.4–74.6)   1.66	(1.12–2.48) 0.013  1.92	(1.25–2.95) 0.003 
 1 255	(5.1) 193 75.7	(69.9–80.8)   2.56	(1.82–3.61) <0.001  2.52	(1.75–3.62) <0.001 
 3 291	(5.9) 244 83.8	(79.1–87.9)   4.27	(2.97–6.15) <0.001  3.49	(2.41–5.07) <0.001 
*CMW,	craft	and	manual worker; OR, odds ratio; SARS-CoV-2,	severe	acute	respiratory	syndrome	coronavirus	2. 









seropositive. Seropositivity ranged from 54.9% (95% 
CI 50.2%–59.4%) for CMW community 5 to 83.8% 
(95% CI 79.1%–87.7%) for CMW community 3 (Figure 
1, panel A). The pooled mean for SARS-CoV-2 sero-
positivity across the 10 CMW communities was 66.1% 
(95% CI 61.5%–70.6%).
Of 2,016 real-time RT-PCR tests using nasopha-
ryngeal swab specimens collected during this study 
for these CMWs, 112 (5.6%, 95% CI 4.6%–6.6%) were 
positive. Real-time RT-PCR positivity ranged from 
0.0% (95% CI 0.0%–3.9%) for CMW community 1 and 
0.0% (95% CI 0.0%–9.0%) for CMW community 8 to 
10.5% (95% CI 7.4%–14.8%) for CMW community 3 
(Figure 1, panel B). Pooled mean real-time RT-PCR 
positivity across the 6 CMW communities in which 
real-time RT-PCR testing was conducted was 3.9% 
(95% CI 1.6%–6.9%). The Ct values ranged from 15.8 to 
37.4 (median 34.0) (Figure 2). Most (79.5%) real-time 
RT-PCR–positive persons had Ct values >30, sugges-
tive of no active infection (31,32). Major differences in 
real-time RT-PCR positivity were found by national-
ity and CMW community (Appendix Table 2).
Infection positivity (antibody or real-time RT-PCR 
positive) ranged from 62.5% (95% CI 58.3%–66.7%) for 
CMW community 4 to 83.8% (95% CI 79.1%–87.7%) 
for CMW community 3 (Figure 1, panel C). Pooled 
mean infection positivity across the 6 CMW commu-
nities with antibody and RT-PCR results was 69.5% 
(95% CI 62.8%–75.9%).
Data were linked to the national SARS-CoV-2 real-
time RT-PCR testing and hospitalization database. Of 
the 3,199 antibody-positive CMWs, 1,012 (31.6%, 95% 
CI 30.0%–33.3%) were previously given a diagnosis 
of SARS-CoV-2 infection (had a record of a real-time 
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Table 2. Characteristics	of	CMW	community	1	and	associations	with	SARS-CoV-2	seropositivity	 (detectable	antibodies	 in	serologic	
samples)	including	sociodemographics,	history	of	exposure,	and	symptoms,	Qatar* 





No. %§	(95%	CI) p	value OR	(95%	CI) p	value¶ 
Sex        
 M 240	(94.1) 189 78.8	(73.0–83.7) <0.001  Referent  
 F 15	(5.9) 4 26.7	(7.8–55.1)   0.10	(0.03–0.32) <0.001 
Age, y        
 <29 105	(41.2) 84 80.0	(71.1–87.2) 0.322  Referent  
 30–39 111	(43.5) 83 74.8	(65.6–82.5)   0.74	(0.39–1.41) 0.360 
 40–49 27	(10.6) 19 70.4	(49.8–86.2)   0.59	(0.23–1.54) 0.284 
 >50 12	(4.7) 7 58.3	(27.7–84.8)   0.35	(0.10–1.21) 0.098 
Nationality        
 Other# 48	(18.8) 23 47.9	(33.3–62.8) <0.001  Referent  
 Indian 32	(12.5) 20 62.5	(43.7–78.9)   1.81	(0.73–4.51) 0.202 
 Nepalese 157	(61.6) 132 84.1	(77.4–89.4)   5.74	(2.82–11.67) <0.001 
 Bangladeshi 18	(7.1) 18 100.0	(81.5–100.0)   Omitted	by	model NA 
Education	level        
 Intermediate or lower 101	(39.6) 88 87.1	(79.0–93.0) <0.001  Referent  
 Secondary/high	school/vocational 80	(31.4) 69 86.3	(76.7–92.9)   0.93	(0.39–2.20) 0.863 
 University 27	(10.6) 17 63.0	(42.4–80.6)   0.25	(0.09–0.67) 0.005 
 Missing 47	(18.4) 19 40.4	(26.4–55.7)   0.10	(0.04–0.23) <0.001 
Contact	with	an	infected	person        
 No 124	(48.6) 93 75.0	(66.4–82.3) 0.303  Referent  
 Yes 14	(5.5) 13 92.9	(66.1–99.8)   4.33	(0.54–34.48) 0.166 
 Unknown/missing 117	(45.9) 87 74.4	(65.5–82.0)   0.97	(0.54–1.73) 0.909 
Symptoms	in	the	past	2	weeks**        
 Asymptomatic 184	(72.2) 148 80.4	(74.0–85.9) <0.001  Referent  
 1 16	(6.3) 16 100.0	(79.4–100.0)   Omitted	by	model NA 
 >2 12	(4.7) 12 100.0	(73.5–100.0)   Omitted	by	model NA 
 Missing 43	(16.9) 17 39.5	(25.0–55.6)   0.16	(0.08–0.32) <0.001 
Symptoms required medical attention        
 No 210	(82.4) 174 82.9	(77.1–87.7) <0.001  Referent  
 Yes 3	(1.2) 3 100.0	(29.2–100.0)   Omitted	by	model NA 
 Unknown/missing 42	(16.5) 16 38.1	(23.6–54.4)   0.13	(0.06–0.26) <0.001 
*CMW,	craft	and	manual	worker;	NA,	not	applicable;	OR,	odds	ratio;	SARS-CoV-2,	severe	acute	respiratory	syndrome	coronavirus	2. 
†Percentage	of	total	sample. 










RT-PCR–confirmed positive result before this study). 
No records of previous real-time RT-PCR positive test 
results were found for the remaining 2,187 antibody-
positive CMWs. For the CMW communities that were 
previously part of broad real-time RT-PCR testing be-
cause of a case identification or a random testing cam-
paign, the diagnosis rate ranged from 28.0% (95% CI 
19.1%–38.2%) for CMW community 8 to 82.9% (95% 
CI 76.8%–87.9%) for CMW community 1. In instances 
in which no such broad real-time RT-PCR testing was 
conducted, the diagnosis rate was only 13.2% (95% 
CI 10.7%–16.1%) for CMW community 10, 7.4% (95% 
CI 4.7%–11.2%) for CMW community 2, and 0.4% 
(95% CI 0.0%–2.3%) for CMW community 3. Only 
a small fraction of antibody-negative persons, 14 of 
1,771 (0.8%, 95% CI 0.4%–1.3%), had been previously 
given a diagnosis of being real-time RT-PCR positive 
(Appendix Table 3).
Of the total sample, 21 persons had a hospitaliza-
tion record associated with a SARS-CoV-2 infection 
diagnosis, of whom, infection severity per WHO clas-
sification was mild for 5, moderate for 10, severe for 
5, and critical for 1. All 21 persons eventually cleared 
their infection and were discharged from the hospital. 
All of these persons were also antibody positive. Ac-
cordingly, the proportion of those persons who had a 
confirmed severe or critical infection of the 3,233 per-
sons who had a laboratory-confirmed infection (anti-
body or real-time RT-PCR positive result) was 0.2% 
(95% CI 0.1%–0.4%).
We linked our data to records of 2 recently com-
pleted studies. These studies, which assessed rein-
fection in Qatar in a cohort of >130,000 real-time RT-
PCR–confirmed infected persons (18) and a cohort of 
>43,000 antibody-positive persons (L.J. Abu-Raddad 








study participants whose results were confirmed by 
using viral genome sequencing.
Discussion
Our results support that herd immunity has been 
reached (or at least nearly reached) in these CMW 
communities, and that the level of herd immunity 
needed for SARS-CoV-2 infection is a proportion of 
the population infected of ≈65%–70%. This conclu-
sion has been reached considering the following lines 
of evidence. First, these CMW communities had com-
parable seroprevalences of ≈65%–70%. Second, real-
time RT-PCR positivity was low and most of those 
who were real-time RT-PCR positive had a high Ct 
suggestive of an earlier rather than recent infection 
(31,32). Third, only a few persons had active infection 
(Ct <25) and no major infection cluster was identified 
in any of these CMW communities during this study 
or thereafter (suggestive of isolated infections and 
unsustainable infection transmission for clusters to 
occur). Fourth, 2 recent studies from Qatar reported 
an efficacy >90% for natural infection against rein-
fection for >7 months after primary infection (18; L.J. 
Abu-Raddad et al., unpub. data), in addition to other 
evidence on the durability of immunity (33–35). Fifth, 
the level of 65%–70% infection exposure is in concor-
dance with that predicted by using the classical for-
mula for herd immunity of 1 – 1/R0 (36,37); R0, the 
basic reproduction number, as 2.5–4.0 (38,39).
Although large clusters of infection were com-
mon in such CMW communities before and around 
the epidemic peak toward end of May, that time is 
several weeks before the launch of this study. Thus, 
no such major cluster has been subsequently identi-
fied in such CMW communities in Qatar, despite the 
progressive easing of the social and physical distanc-
ing restrictions since June 15, 2020.
These findings indicate that reaching herd immu-
nity in such largely homogenous communities requires 
high exposure levels of ≈65%–70%. However, true herd 
immunity might have been reached even at a lower 
proportion of the population infected. Mathematical 
modeling indicates that infection exposure for a novel 
infection (especially in the first cycle) can considerably 
overshoot the classical herd immunity level of 1 – 1/R0, 
more so if the social contact rate within this community 
is homogeneous (Appendix Figure 1). Heterogeneity in 
the social contact rate can reduce the final proportion of 
the population that needs to be infected to reach herd 
immunity (Appendix Figure 1) (37; R. Aguas et al., Ox-
ford University, pers. comm., 2021 Feb 1).
The severity rate for SARS-CoV-2 infection was 
low (0.2%), possibly because of the young age of the 
CMWs. No COVID-19 deaths were reported in these 
CMW communities. In communities in which no pre-
vious, broad real-time RT-PCR testing was conducted, 
<15% of the antibody-positive persons had ever been 
given a diagnosis as being real-time RT-PCR positive 
before this study. There was a large difference in in-
fection exposure between women and men (Table 1). 
This difference, with the variable proportion of wom-
en across these communities, also explains part of the 
variation seen in the overall seroprevalence across 
these communities (Figure 1; Appendix Figure 2). 
This finding might be attributed to women and men 
living in different housing accommodations and hav-
ing different work roles. Women, a small minority in 
these CMW communities, live in small shared accom-
modations as opposed to the large ones hosting men.
Differences in results by nationality (Table 1), are 
explained by nearly all Bangladeshis and Nepalese 
and most Indians being the workers in these commu-
nities, because a proportion of Indians and much of 
the other nationalities held administrative or manage-
rial positions that had lower social contact rates and 
possibly lived in different accommodations than most 
of the workers. No major differences in infection ex-
posure by age were found, although there was a ten-
dency for persons >40 years of age to have lower in-
fection exposure (Appendix Table 1), possibly caused 
by different occupations within these communities.
Our study’s limitations included that, by design, 
the study was specifically conducted in select CMW 
communities, and therefore findings might not be 
representative nor generalizable to the wider CMW 
population in Qatar. The small and variable propor-







findings might not also be generalizable to women 
in these communities. Response rate could not be 
precisely ascertained given uncertainty around the 
number of CMWs who were aware of the invitation 
to participate, but on the basis of employer-reported 
counts of the size of each community, the response 
rate was >50%, and participants expressed high in-
terest in knowing their antibody status. The validity 
of study outcomes is contingent on the sensitivity 
and specificity of the used assays. However, labora-
tory methods were based on high-quality commer-
cial platforms, and each diagnostic method was vali-
dated in the laboratory before its use. The antibody 
assay is one of the best available and extensively 
used and investigated commercial platforms; it has 
a specificity >99.8% (22,40,41), indicating that false-
positive results, or positive results due to cross-re-
activity with other common cold coronaviruses, are 
not likely.
In conclusion, some of the CMW communities in 
Qatar, who constituted ≈60% of the total population 
(7), have reached or nearly reached herd immunity 
for SARS-CoV-2 infection. Although achieving herd 
immunity at a national level is difficult within a few 
months (42), herd immunity could be achieved in 
specific communities within a few months. In such 
relatively homogenous communities, reaching herd 
immunity required infection of 65%–70% of the 
members of the community. These findings suggest 
that the SARS-CoV-2 epidemic in a homogenous 
population is likely to be sustainable until at least 
two thirds of the population become infected. This 
finding also suggests that a SARS-CoV-2 vaccine 
needs at least 65%–70% efficacy at universal cover-
age for herd immunity to be achieved in a population 
not exposed to SARS-CoV-2 infection (43,44; H.H. 
Ayoub et al., unpub. data). Alternatively, herd im-
munity might be reached at a vaccination coverage 
of ≈75% if vaccine efficacy is 95%, similar to that of 
the recently licensed SARS-CoV-2 vaccines (45,46).
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Lassa fever, a virus spread through the inhala� on of 
rodent excreta, o� en causes mild, infl uenza-like 
symptoms. But in severe cases, pa� ents can face bleeding, 
neurological symptoms, and a death rate up to 70 percent. 
Lassa fever alters platelet func� on and blood clo�  ng, but 
the exact mechanisms involved remain a mystery. 
Now, researchers are searching for answers.
In this EID podcast, Dr. Brian Sullivan, a researcher and
instructor at La Jolla Ins� tute for Immunology, discusses 
how Lassa fever aff ects the vascular system.
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Endotheliopathy and Platelet Dysfunc� on 
as Hallmarks of Fatal Lassa Fever
